The cholesterol shot you couldn’t afford is now a pill

FDA approved Merck’s first noninjectable PCSK9-blocking cholesterol pill, Lipfendra, for patients with persistent artery-clogging cholesterol despite statins. In two studies, LDL fell >55% (6 months) in a trial of ~3,000 patients and averaged 59% vs placebo, with side effects (e.g., dizziness, diarrhea) similar to placebo; benefit persisted only slightly lower after a year, though dosing requires an empty stomach. The ultra-fast FDA review under its public-interest pathway is likely to support incremental uptake after years of access limits tied to expensive injectables.

Analysis

The first-order read is negative for AMGN, but the larger signal is that the PCSK9 market is likely to shift from a narrow specialty channel into a broader primary-care distribution model. That expands the addressable pool, but it also moves the competitive battleground from pure efficacy to adherence, net pricing, and formulary placement — areas where an oral product can win if Merck discounts aggressively. For AMGN, the key question is not whether its injectables remain clinically relevant; it is whether payer economics now force a faster erosion in premium pricing and prior-authorizations over the next 6-18 months.

Near term, I would expect only modest immediate pressure on AMGN because the pill still has friction: empty-stomach dosing, likely step edits, and payer skepticism until there is hard cardiovascular-outcomes data. The bigger second-order effect is on physician behavior: once cardiologists can offer a pill, diagnosis and treatment rates for patients who would never start an injectable may rise, which could partially offset cannibalization across the class. That means the category may grow faster than consensus while individual incumbent economics compress.

The contrarian view is that this is less of a pure market-share loss for Amgen than the market will initially assume. Injectable PCSK9s remain more convenient for some high-adherence patients, and if Merck’s launch relies on heavy rebateing, the economics may be less disruptive than the LDL headline implies. The real falsifier for a bearish AMGN view is if Merck announces rapid formulary wins or if utilization data show the oral product is taking share without a meaningful price concession within the next 1-2 quarters.

Key Decisions for Investors

• Short AMGN on strength into the first 1-2 trading sessions if the stock gaps up on headline relief; use a 2-8 week horizon and cover if management signals no pricing pressure or if launch commentary suggests limited payer uptake.
• Pair trade: long MRK / short AMGN for 1-3 months, targeting class expansion plus share shift; thesis breaks if Merck discloses weak adherence or if payers impose restrictive access comparable to injectables.
• If you want lower beta exposure, buy IBB or XBI only on confirmation of channel expansion data, not the approval alone; the move is more about redistribution inside the cardiometabolic basket than a broad biotech re-rating.